1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

Autor:	L. Albiges, H.P. Gurney, V. Atduev, C. Suárez, M.A. Climent Duran, D. Pook, P. Tomczak, P. Barthelemy, J-L. Lee, T. Nalbandian, V. Stus, T. Ferguson, P. Wiechno, E. Gokmen, L. Lacombe, C. Gedye, R. Perini, M. Sharma, null C. Li, C-H. Lee
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1204-S1205
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::59cf5d2461e89d40574e3e10c399a0e3 https://doi.org/10.1016/j.annonc.2022.07.1551 Zobrazit plný text záznamu